Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Drug Enforcement Administration (DEA)
Pharma
Sage, Biogen call an audible on pricing strategy for Zurzuvae
Sage and Biogen will charge $15,900 for their postpartum depression treatment Zurzuvae, which was approved in August and is set to launch in December.
Kevin Dunleavy
Nov 7, 2023 3:24pm
FDA, DEA urge production push to resolve stimulant shortages
Aug 3, 2023 8:05am
Idorsia requests to de-schedule DORA insomnia drugs
Apr 7, 2023 10:55am